Lets hope that some of the pundits recently trumpeting Elanss nanotechnology success story didnt put all their eggs in one basket, as Elans shares crashed by 70% today following a suspected connection between a US patients death and their new multiple sclerosis drug Tysabri. The good year that we noted back in January seesm have come to a premature end.
The quote from a Dublin stockbroker illustrates how much was really thought of the financial impact of their Nanocrystal technology. “Most of the value in the company was in Tysabri Now there’s a question mark over it.” The same hold true for a number of other publicly quoted companies, and it is always good practice to attempt to determine how much values is actually nanotech related.